Kestrel

About Ataraxis AI

Ataraxis AI is a clinical-stage AI company spun out of New York University in 2023, focused on developing and deploying AI-powered tools to improve cancer prognosis and treatment selection. The company has raised a $20.4 million Series A round and has launched its first product, Ataraxis Breast, a prognostic tool that delivers results within 24 hours using existing pathology slides. Backed by a world-class team and advisors like AI pioneer Yann LeCun, Ataraxis is collaborating with top international cancer centers to validate and implement its technology across multiple cancer types.

Therapeutic Areas